Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Scientists develop new diagnostic procedure for pulmonary aspergillosis

Scientists develop new diagnostic procedure for pulmonary aspergillosis

SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion

SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion

How resistant is the SARS-CoV-2 Brazilian variant to antibodies?

How resistant is the SARS-CoV-2 Brazilian variant to antibodies?

Compromised immunity can allow SARS-CoV-2 to evade the immune system

Compromised immunity can allow SARS-CoV-2 to evade the immune system

New study tests how mutations in SARS-CoV-2 affect antibody neutralization

New study tests how mutations in SARS-CoV-2 affect antibody neutralization

Translational research results in promising combination therapeutic candidate for type 1 diabetes

Translational research results in promising combination therapeutic candidate for type 1 diabetes

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

Current vaccines and therapies may be less effective at neutralizing new SARS-CoV-2 variants

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

Study: Monoclonal antibody 'cocktail' effective against all known COVID-19 variants

ACTIV-3 clinical trial evaluating investigational COVID-19 therapies closes enrollment in two sub-studies

ACTIV-3 clinical trial evaluating investigational COVID-19 therapies closes enrollment in two sub-studies

Study: Repurposed arthritis drug did not improve outcomes of patients with severe COVID-19 pneumonia

Study: Repurposed arthritis drug did not improve outcomes of patients with severe COVID-19 pneumonia

NLRP3 inflammasome inhibitors may help treat early COVID-19, says study

NLRP3 inflammasome inhibitors may help treat early COVID-19, says study

Basigin does not facilitate SARS-CoV-2 entry, say researchers

Basigin does not facilitate SARS-CoV-2 entry, say researchers

SARS-CoV-2 variants emerge during humoral immunity phase of acute COVID-19

SARS-CoV-2 variants emerge during humoral immunity phase of acute COVID-19

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

Current monoclonal antibodies less potent against SARS-CoV-2 variants

Current monoclonal antibodies less potent against SARS-CoV-2 variants

FDA issues guidance for medical product developers to address the emergence of SARS-CoV-2 variants

FDA issues guidance for medical product developers to address the emergence of SARS-CoV-2 variants

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

Rural hospital remains entrenched in Covid ‘war’ even amid vaccine rollout

Rural hospital remains entrenched in Covid ‘war’ even amid vaccine rollout

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.